If you are wondering whether USA Compression Partners at around US$27.29 is priced attractively or not, the key is to separate share price excitement from underlying value.
The unit price is down 2.4% over the last 7 days and 0.1% over the last 30 days, yet it still shows a 14.7% return year to date and 10.3% over the past year, with longer term returns of 66.1% over 3 years and 207.2% over 5 years.
These moves sit against a backdrop of ongoing interest in energy infrastructure partnerships...
GBank Financial Holdings (GBFH) just closed out FY 2025 with fourth quarter revenue of US$20.9 million and basic EPS of US$0.52, supported by trailing twelve month revenue of US$72.2 million and EPS of US$1.46. Over recent periods, quarterly revenue has moved from US$16.2 million in Q4 2024 to US$20.9 million in Q4 2025, while quarterly EPS shifted from US$0.37 to US$0.52. This may prompt investors to focus on how earnings power and profit margins are holding up.
See our full analysis for...
Event driven snapshot of Versigent
Versigent (VGNT.WI) recently attracted attention after its when-issued shares closed at $31.00, giving the Switzerland based Aptiv subsidiary a market value of about $2.1 billion in electrical distribution solutions.
See our latest analysis for Versigent.
That 2.65% 1 day share price return, with the share price at $31.00, sets the tone for Versigent’s early trading and may indicate that investors are adjusting expectations around its role in electrical...
Analog Devices is scheduled to present at the 2026 International Conference on Display Technology.
The company plans to highlight its ongoing R&D efforts and role in the evolving display technology market.
The appearance gives investors another reference point for how Analog Devices is positioning itself alongside global peers in high-value display applications.
For investors tracking NasdaqGS:ADI, this conference slot comes with the stock trading at $303.1 and showing sizeable multi year...
Wondering if Axogen at around US$31.32 is still offering value or if the easy gains are behind it? This article walks through what the current price actually reflects.
The stock has had a mixed recent run, with a 4.0% decline over the last week and a 1.3% decline over the last month, while still sitting on a 1.0% return year to date and a 75.9% return over the last year.
Those moves sit within a longer track record that includes a 223.2% return over three years and a 56.8% return over five...
If you are wondering whether Primoris Services at around US$134 per share still offers value after a strong run, the key is to separate price excitement from what the business might actually be worth.
The stock shows a 134.8% return over the last year and a very large 3 year return, even though the last 7 days and 30 days reflect declines of 5.7% and 10.8% respectively, and the year to date return sits at 2.9%.
Recent coverage has focused on Primoris Services as a construction and...
For investors considering whether Restaurant Brands International at around US$73.76 represents fair value or a potential opportunity, this article focuses on what the current share price implies.
The stock has declined 1.7% over the last 7 days, with returns of 2.9% over 30 days, 8.8% year to date, 14.8% over 1 year, 20.9% over 3 years, and 34.0% over 5 years. These figures can influence how investors think about both potential upside and risk.
Recent news coverage has largely focused on...
Wondering if Cactus at around US$46.70 is priced attractively or already reflects its strengths? This article walks through the key signals that matter for valuation-focused investors.
The stock has seen a 2.2% decline over the last week and a 13.5% decline over the last month, while still showing returns of 3.2% over 1 year, 11.4% over 3 years and 58.7% over 5 years.
These moves sit against a backdrop where investors are watching sector-wide sentiment and company-specific developments...
Fermi has yet to secure a cornerstone tenant for its flagship Project Matador campus, despite progressing permits that target 17 GW of power capacity.
The company has made substantial capital commitments and lined up equipment financing, but no anchor customer contract has been confirmed.
This gap between infrastructure build out and tenant sign on is raising questions about future revenue visibility and the private grid model.
For investors watching NasdaqGS:FRMI, the lack of an anchor...
Commercial Metals increased its regular quarterly dividend for the 246th consecutive quarter.
The latest dividend raise extends a multidecade record of uninterrupted quarterly increases.
The move signals continued commitment to returning cash to shareholders.
For investors watching NYSE:CMC, this dividend hike arrives with the stock trading around $60.09. The share price has seen a 31.8% gain over the past year and a 103.2% gain over the past five years, while the year-to-date return stands...
Index removal puts fresh focus on Ziff Davis
Ziff Davis (ZD) has been removed from the NASDAQ Internet Index, an adjustment that can prompt portfolio shifts for index-tracking funds and encourage investors to reassess how the stock fits within internet sector exposures.
See our latest analysis for Ziff Davis.
The latest index exit comes after a sharp 54.8% 30 day share price return, alongside a 23.3% year to date share price gain. The 1 year total shareholder return of 11.6% contrasts with a...
Regulatory and consumer groups in Ohio are challenging American Electric Power Company's cost recovery approach for a $1.1b Grid Growth Ohio transmission project.
The dispute centers on the proposed return on equity and formula rate, which opponents argue may shift data center related costs onto Ohio ratepayers without sufficient safeguards.
The case is now before the Federal Energy Regulatory Commission, putting the project structure and cost allocation under closer regulatory review.
For...
Sigma Lithium (NasdaqCM:SGML) just posted its FY 2025 third quarter scorecard with revenue of US$28.5 million and a basic EPS loss of US$0.10, alongside net income excluding extra items of a US$11.6 million loss. The company has seen quarterly revenue move between US$16.9 million and US$47.7 million over the past three reported quarters, with basic EPS ranging from a profit of US$0.04 to losses of US$0.17. Trailing twelve month EPS stands at a loss of US$0.30 on revenue of US$139.0 million...
In March 2026, Protagonist Therapeutics reported one-year Phase 3 data for ICOTYDE (icotrokinra) in moderate to severe plaque psoriasis, showing sustained skin clearance and a favorable safety profile as the first oral IL-23 receptor–targeted peptide.
The data, including adolescent results through Week 52, underline ICOTYDE’s potential as a once-daily pill alternative to injectable treatments and highlight the company’s peptide discovery platform.
We’ll now look at how ICOTYDE’s...
At the March 12, 2026 BofA Securities Information & Business Services Conference, First Advantage Corporation highlighted 17% fourth-quarter revenue growth, a transition toward capital risk management solutions, and board approval of a US$100,000,000 share repurchase program.
The company’s emphasis on expanding beyond background screening into a broader capital risk management platform, supported by about 97% client retention, underlines management’s confidence in scaling the business...
Relay Therapeutics (RLAY) is back in focus after releasing new Phase 1/2 ReDiscover trial data for zovegalisib plus fulvestrant in PI3Ka-mutated, HR+/HER2- metastatic breast cancer, supporting its selected Phase 3 dosing regimen.
See our latest analysis for Relay Therapeutics.
The latest trial update comes after a sharp move in the stock, with a 1 day share price return of negative 5.14% and a 30 day share price return of negative 6.43%. However, a 1 year total shareholder return of 266.41%...
Global Partners (GLP) has drawn investor attention after its recent share moves, with the stock closing at US$44.37. That price appears alongside mixed recent returns and a value score of 3.
See our latest analysis for Global Partners.
The recent pullback, with a 1-day share price return of 1.40% decline and a 7-day share price return of 4.42% decline, contrasts with a 90-day share price return of 3.98% and multi year total shareholder returns that remain strongly positive. This points to...
Arcellx (ACLX) has drawn attention after fresh performance data on its lead cancer immunotherapies prompted investors to reassess both the company’s clinical pipeline and its recent share price strength over the past 3 months.
See our latest analysis for Arcellx.
Over the past year Arcellx’s share price return of 80.88% year to date and 80.14% over 90 days, compared with a 74.65% one year total shareholder return and 290.09% three year total shareholder return, points to strong momentum...
What Gevo’s North Dakota expansion announcement means for the stock
Gevo (GEVO) has attracted fresh attention after outlining plans to potentially add a second low carbon ethanol plant at its North Dakota site. This would more than double the current nameplate capacity.
See our latest analysis for Gevo.
The expansion news arrives after a strong run in the shares, with a 30 day share price return of 38.46% and a year to date share price return of 22.33%, while the 1 year total shareholder...
